Bioventure, a capital investor in life sciences, fosters growth in biotech, drug discovery, and healthcare services with robust post-investment support.
Location
Suzhou, Jiangsu, CN
Founded
2013
BioVenture is a capital investor specializing in the life sciences sector, focusing on early-stage venture capital investments. The firm targets biotechnology, drug discovery, medical devices, and healthcare services companies that exhibit high growth potential and strong management teams. Established in 2013, BioVenture manages a fund size of 540 million yuan and typically invests in seed, Series A, and other early-stage rounds.
Notable portfolio companies include AI Therapeutics, MID Labs, NeuExcell Therapeutics, Sanegene Bio, Synaptic Medical, and Tavotek Biotherapeutics. BioVenture is known for providing robust post-investment support to its portfolio companies, fostering growth through strategic guidance and capital. The firm's investment philosophy emphasizes identifying high-potential ventures within the life sciences domain and nurturing them to achieve significant development milestones.
BioVenture - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
